Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; ROCK inhibitor platform, a rho-associated coiled-coil kinase inhibitor, which is in preclinical development to treat specific fibrotic and neurodegenerative diseases; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Chiromics, LLC; MeiraGTx Limited; AbbVie Inc.; Zydus Pharmaceuticals USA, Inc.; Jinghua Pharmaceutical Group Co., Ltd.; and Camber Pharmaceuticals, Inc. The company is headquartered in New York, New York.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:KDMN
CUSIPN/A
Phone212-308-6000
Debt
Debt-to-Equity RatioN/A
Current Ratio3.10
Quick Ratio3.08
Price-To-Earnings
Trailing P/E Ratio-2.36
Forward P/E Ratio-3.55
P/E GrowthN/A
Sales & Book Value
Annual Sales$12.26 million
Price / Sales30.81
Cash FlowN/A
Price / CashN/A
Book Value($0.49) per share
Price / Book-6.82
Profitability
EPS (Most Recent Fiscal Year)($1.42)
Net Income$-79,770,000.00
Net Margins-856.59%
Return on EquityN/A
Return on Assets-74.68%
Miscellaneous
Employees101
Outstanding Shares113,100,000
Market Cap$377.76 million
Kadmon (NYSE:KDMN) Frequently Asked Questions
What is Kadmon's stock symbol?
Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."
How were Kadmon's earnings last quarter?
Kadmon Holdings Inc (NYSE:KDMN) posted its quarterly earnings data on Thursday, August, 9th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.50. The firm had revenue of $0.36 million for the quarter, compared to the consensus estimate of $0.90 million. View Kadmon's Earnings History.
When is Kadmon's next earnings date?
What price target have analysts set for KDMN?
4 brokers have issued 12-month price objectives for Kadmon's shares. Their predictions range from $3.00 to $25.00. On average, they expect Kadmon's stock price to reach $13.25 in the next twelve months. This suggests a possible upside of 296.7% from the stock's current price. View Analyst Price Targets for Kadmon.
What is the consensus analysts' recommendation for Kadmon?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kadmon.
Who are some of Kadmon's key competitors?
Some companies that are related to Kadmon include Insmed (INSM), Tricida (TCDA), Theravance Biopharma (TBPH), Uniqure (QURE), Biohaven Pharmaceutical (BHVN), Wave Life Sciences (WVE), TherapeuticsMD (TXMD), Kiniksa Pharmaceuticals (KNSA), Deciphera Pharmaceuticals (DCPH), Impax Laboratories (IPXL), ImmunoGen (IMGN), IMMURON Ltd/S (IMRN), Esperion Therapeutics (ESPR), Endocyte (ECYT) and Omeros (OMER).
Who are Kadmon's key executives?
Kadmon's management team includes the folowing people:
- Dr. Harlan W. Waksal, Pres, CEO & Director (Age 65)
- Mr. Konstantin Poukalov, Exec. VP, CFO & Principal Accounting Officer (Age 34)
- Mr. Steven N. Gordon, Chief Admin., Compliance & Legal Officer, Exec. VP & Gen. Counsel (Age 50)
- Dr. John L. Ryan, Chief Medical Officer & Exec. VP (Age 75)
- Wei Chen Ph.D., Associate Director of Immunology
When did Kadmon IPO?
(KDMN) raised $101 million in an initial public offering (IPO) on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.
Has Kadmon been receiving favorable news coverage?
News articles about KDMN stock have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kadmon earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave press coverage about the company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Kadmon.
Who are Kadmon's major shareholders?
Kadmon's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vivo Capital LLC (13.27%), Acuta Capital Partners LLC (11.50%), BlackRock Inc. (6.05%), Marshall Wace LLP (2.16%), VHCP Management II LLC (1.79%) and Northern Trust Corp (0.70%). Company insiders that own Kadmon stock include Daniel S Loeb, Eugene Bauer, Goldentree Asset Management Lp, Harlan Waksal, Konstantin Poukalov and Steven N Gordon. View Institutional Ownership Trends for Kadmon.
Which institutional investors are selling Kadmon stock?
Which institutional investors are buying Kadmon stock?
KDMN stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, BlackRock Inc., Acuta Capital Partners LLC, VHCP Management II LLC, Marshall Wace LLP, Northern Trust Corp, Renaissance Technologies LLC and Asymmetry Capital Management L.P.. Company insiders that have bought Kadmon stock in the last two years include Daniel S Loeb, Eugene Bauer, Harlan Waksal, Konstantin Poukalov and Steven N Gordon. View Insider Buying and Selling for Kadmon.
How do I buy shares of Kadmon?
Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kadmon's stock price today?
One share of KDMN stock can currently be purchased for approximately $3.34.
How big of a company is Kadmon?
Kadmon has a market capitalization of $377.76 million and generates $12.26 million in revenue each year. The company earns $-79,770,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. Kadmon employs 101 workers across the globe.
How can I contact Kadmon?
Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 212-308-6000 or via email at [email protected]
MarketBeat Community Rating for Kadmon (NYSE KDMN)
MarketBeat's community ratings are surveys of what our community members think about Kadmon and other stocks. Vote "Outperform" if you believe KDMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KDMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
